8-K: Viking Therapeutics Secures Manufacturing Agreement with CordenPharma for VK2735 Commercialization

Viking Therapeutics has entered into a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ensuring sufficient supply for potential multi-billion-dollar annual product opportunity.

Summary

• Viking Therapeutics has signed a strategic manufacturing agreement with CordenPharma to secure the supply of VK2735, its dual GLP-1/GIP agonist.
• The agreement covers both the active pharmaceutical ingredient (API) and finished product supply.
• Viking will make prepayments totaling $150 million between 2025 and 2028 to secure dedicated capacity.
• CordenPharma will dedicate a manufacturing line to Viking and provide additional capacity if needed.
• The agreement includes dedicated fill/finish capacity for 100 million autoinjectors and an additional 100 million vial/syringe products annually, plus over 1 billion oral tablets.
• The initial term of the agreement is eight years, with automatic three-year renewal periods.

Sentiment

Score: 8

Explanation: The document is positive due to the strategic manufacturing agreement, which secures long-term supply and supports potential commercial success of VK2735. The financial commitment and dedicated capacity indicate strong confidence in the product's future.

Positives

• The agreement secures long-term supply of VK2735 for both subcutaneous and oral formulations.
• Dedicated manufacturing lines and capacity ensure reliable production.
• The agreement supports a potential multi-billion-dollar annual product opportunity.
• Viking retains ownership of all global rights to VK2735.
• CordenPharma's established presence in commercial peptide manufacturing provides confidence in their ability to deliver supply.

Risks

• The agreement is subject to customary risks associated with manufacturing and supply agreements.
• The success of VK2735 is dependent on clinical trial outcomes and regulatory approvals.
• The actual commercial demand for VK2735 may differ from anticipated levels.
• There are risks associated with the manufacturing of API and product supply for VK2735.

Future Outlook

Viking expects the agreement to provide sufficient long-term supply of both subcutaneous and oral VK2735 product forms to support a potential multi-billion-dollar annual product opportunity and plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the second quarter of 2025.

Management Comments

• Brian Lian, Ph.D., chief executive officer of Viking Therapeutics, stated that they are excited to enter into this agreement with one of the world's leading CDMOs in the peptide space.
• Brian Lian expressed confidence in CordenPharma's ability to deliver supply commensurate with anticipated commercial demand.
• Brian Lian noted that CordenPharma's ability to provide dedicated capacity across the supply chain makes them a uniquely qualified partner.

Industry Context

The agreement positions Viking to compete in the growing market for obesity and metabolic disorder treatments, where GLP-1 and dual GLP-1/GIP agonists are gaining prominence, as exemplified by drugs like Ozempic, Rybelsus, Wegovy, Mounjaro, and Zepbound.

Comparison to Industry Standards

• The agreement aims to secure manufacturing capacity similar to that of companies producing established GLP-1 agonists like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound).
• The dedicated capacity for 100 million autoinjectors and 100 million vial/syringe products annually is comparable to the production scales required for successful injectable obesity treatments.
• Securing over 1 billion oral tablets annually positions Viking to compete with oral GLP-1 agonists like Rybelsus.

Stakeholder Impact

• Shareholders: The agreement is likely to be viewed positively by shareholders as it de-risks the commercialization of VK2735.
• Employees: The agreement supports the company's growth and provides job security.
• Customers: The agreement ensures a reliable supply of VK2735 if it receives regulatory approval.
• Suppliers: The agreement strengthens Viking's relationship with CordenPharma.

Next Steps

• Viking plans to file the CordenPharma Agreements with its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025.
• Viking plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the second quarter of 2025.

Key Dates